• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Silo Pharma, Inc. - Common Stock (NQ:SILO)

    4.430 +0.110 (+2.55%)
    Streaming Delayed Price Updated: 11:56 AM EDT, Aug 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Silo Pharma, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Subsidiary QwikAgents Joins AMD AI Developer Program
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
    Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents 
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
    NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing 
    From Silo Pharma, Inc.
    Via GlobeNewswire
    NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances SPC-15 Intranasal PTSD Program With Device Robustness Study
    Via Investor Brand Network
    News headline image
    Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
    From Silo Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Launches Ibogaine-Based TBI Therapeutics Initiative
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
    From Silo Pharma, Inc.
    Via GlobeNewswire
    PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Federal Momentum Advancing Psychedelic Therapeutics Development
    Via Investor Brand Network
    News headline image
    Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
    From Silo Pharma, Inc.
    Via GlobeNewswire
    AINewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Into AI With Qwikagents Asset Acquisition
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
    From Silo Pharma, Inc.
    Via GlobeNewswire
    PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances IP Portfolio With EPO Notice of Intent to Grant Patent
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
    From Silo Pharma, Inc.
    Via GlobeNewswire
    MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Authorizes $1 Million Share Repurchase Program
    Via Investor Brand Network
    News headline image
    Silo Pharma Announces Share Buyback Program
    From Silo Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives Japan Patent Allowance for SPC-15 PTSD Candidate10
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio
    Patent strengthens protection for novel PTSD drug and advances the Company’s international IP strategy 
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Selects Alphaledger’s T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company’s Commitment to Multi-Chain Growth
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    From Silo Pharma, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.